Global Oligonucleotide Synthesis Market Size, Trend & Opportunity Analysis Report, by Product (Oligonucleotides, Equipment/Synthesiser, Reagents, Services), Application (PCR Primers, Sequencing, DNA Microarrays, FISH, Antisense Oligonucleotides), End Use (Academic Research Institutes, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies), and Forecast, 2025-2035
Global Oligonucleotide Synthesis Market Size, Opportunity Analysis and Forecast, 2025-2035
Market Definition and Introduction
The Global Oligonucleotide Synthesis Market was valued at USD 4.34 billion in 2024 and is anticipated to reach USD 12.30 billion by 2035, expanding at a CAGR of 12.34% during the forecast period 2025-2035. This kind of rise is attributed to the significant role played by oligonucleotides in genetic research, diagnostics, therapeutics, and the advancement of biotechnology. With the rapid development of precision medicine, RNA-based therapies, and CRISPR gene editing technologies, the need for custom and high-fidelity oligonucleotide sequences has ever-increasing importance.
Oligonucleotide synthesis services have changed how researchers and biopharma companies perform molecular biology by enabling fast-track development of gene-based diagnostics and therapeutics. From short DNA fragments used in PCR assays to complex antisense oligos for gene silencing, applications of oligonucleotides have spread widely from healthcare to agriculture and synthetic biology. The ever-increasing need for synthetic RNA for vaccines, as highlighted by the COVID-19 pandemic, has put further emphasis on the strategic importance of scalable automated synthesis platforms.
Technological innovations like enzymatic DNA synthesis, microarray-based platforming, and AI-based sequence optimisation tools have
revamped the synthesis landscape. Companies are investing heavily in automation, high-throughput synthesis systems, and robust quality controls to ensure customisation, consistency in yield, and speed to market for oligos. This rapidly changing market represents an opportunity and a challenge: scientific complexity, regulatory scrutiny, and a need for next-generation oligonucleotide design solutions.
Recent Developments in the Industry
- In March 2024, Twist Bioscience Corporation expanded its synthetic biology capabilities by unveiling a suite of high-throughput oligo pools aimed at enabling faster gene assembly and CRISPR screening workflows. These oligos are designed for enhanced fidelity, supporting research in oncology, rare diseases, and drug discovery pipelines.
- In January 2024, Integrated DNA Technologies Inc. (IDT) partnered with Element Biosciences to optimise oligonucleotide primer kits tailored for next-generation sequencing (NGS) on the Element AVITI System. This collaboration enhances sequencing accuracy and scalability, particularly for applications in precision oncology and infectious disease diagnostics.
- In August 2023, Agilent Technologies Inc. announced the expansion of its oligonucleotide production facility to accommodate increasing global demand for therapeutic-grade oligos. The site will specialize in GMP-compliant synthesis for use in RNA interference (RNAi) therapies and antisense drugs, reinforcing the company's strategic positioning in the therapeutics segment.
Market Dynamics
Increased Genomic Research and Demand for Therapeutics Accelerate Market Growth
The most conductive request for custom oligonucleotides for research and therapeutic application is based on the current trend in genomic research initiative growth and the proliferation of personalised medicine. From PCR to gene expression analysis, antisense studies and RNA interference, oligonucleotides are increasingly becoming a pillar in both the diagnostics and therapeutics pipeline. Increasingly, pharmacologic companies add synthetic oligos to their drug development workflows, particularly for their therapies in gene silencing and immune modulation, thereby sustaining a continuous market growth.
Technological Advancement on Automation and Miniaturisation Promoting Efficiency
Massive improvement in yield consistency and cost efficiency due to rapid technological evolution in automated synthesisers and high-throughput array systems. Usage of integrated microfluidic technologies and AI-based design algorithms predicted optimal oligo sequences and reduced synthesis errors. Such miniaturisation is not only shortening turnaround times but also allowing hundreds of sequences to be synthesised in parallel at the same time, bringing their inventions and diagnostic validations a step ahead.
Regulatory Complexity and Cost of High-Purity Oligos as Restraints
However, the bright future of this market is accompanied by some bottlenecks as a result of very close regulatory oversight and the high cost of purification and validation for therapeutic-grade oligos. These are added costs arising from GMP compliance, contamination prevention, and analytical validation. Besides, harmonisation of standards for oligonucleotide therapeutics is absent on the global level, thus impeding cross-border collaboration, especially between manufacturers and clinical-stage companies.
Emerging Opportunities in RNA Therapeutics and Synthetic Biology
The advent of RNA vaccines and therapeutics has created enormous opportunities in the field of oligonucleotide suppliers. With the expanding definition of RNA beyond mRNA vaccines into siRNA and miRNA therapies, the demand for RNA oligos with customised modifications and stability-enhanced improvements has increased exponentially. Moreover, synthetic biology is another emerging domain that will increase and further open the horizon in custom- designed oligonucle otides for research and commercialization occasions; where synthetic biology includes genome editing, bio-circuitry, and engineered microorganisms.
Green Design Trend in Manufacturing and Sustainable Synthesis Platforms
Sustainability is becoming the definitive trend in every industry, in which manufacturers are keen on searching for environmentally friendly synthesis reagents, recycling solvents, and adopting energy-efficient purification methods. Companies adopting green synthesis technologies probably maximise benefits in reducing their environmental footprints while fulfilling the increasingly demanding expectations from global regulators and biopharma clients who are moving to sustainable sourcing.
Attractive Opportunities in the Market
- RNA Therapeutics Boom - The surge in RNA-based drugs and vaccines increases the demand for therapeutic oligos.
- Synthetic Biology Advancements - DNA/RNA synthesis fuels genome engineering, biofoundries, and novel biosystems.
- CRISPR-Cas9 Innovation - High-fidelity guide RNA synthesis is central to genome editing success.
- Automated Synthesis Platforms - Scalable, robotic systems enhance throughput, accuracy, and lab efficiency.
- Enzymatic DNA Synthesis - Enzyme-driven technologies enable longer sequences and reduce synthesis errors.
- On-demand Customization - Personalized reagents and DNA sequences support niche research and diagnostics.
- AI-enhanced Sequence Design - Predictive algorithms optimize sequence specificity and reduce production failures.
- Global Manufacturing Expansion - Regional facilities address supply chain resilience and clinical trial needs.
Report Segmentation
By Product:
- Oligonucleotides
- Product Type (Column-based Oligos, Array-based Oligos)
- Nucleic Acid Type (DNA, RNA)
- Equipment/Synthesiser Reagents
- Services
- Oligo Synthesis (25 nmol, 50 nmol, 200 nmol, 1000 nmol, 10,000 nmol)
- Purification
- Modification
By Application: PCR Primers, PCR Assays and Panels, Sequencing, DNA Microarrays, Fluorescence In Situ Hybridization (FISH), Antisense Oligonucleotides, Other Applications
By End Use: Academic Research Institutes, Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies
By Region: North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia (KSA), Africa Rest of Latin America)
Key Market Players: Thermo Fisher Scientific Inc., Merck KGaA, Integrated DNA Technologies Inc., Agilent Technologies Inc., Eurofins Genomics, LGC Biosearch Technologies, Twist Bioscience Corporation, Bio-Synthesis Inc., GenScript Biotech Corporation, and TriLink BioTechnologies.
Report Aspects
Base Year: 2024
Historic Years: 2022, 2023, 2024
Forecast Period: 2025-2035
Report Pages: 298
Dominating Segments
Oligonucleotide Segment Leads the Market Owing to Its Central Role in Genomics and Therapeutics
Pivotal to the global oligonucleotide synthesis arena, oligonucleotides score big on almost every account because of their essential roles in molecular biology, diagnostics, and therapeutics. DNA and RNA oligos act as platforms for PCR, gene synthesis, antisense therapeutics, and CRISPR-based genome editing. The increasing clinical candidates based on oligonucleotide therapies obligated the manufacturers to upscale production and purity standards. Modifications in array- and column-based synthesis technologies improved throughput and reduced costs for fast custom oligo production. Furthermore, an increase in the demand for RNA oligos in mRNA vaccines and RNA interference further propelled the rapid development of modified nucleic acid chemistries that offer stability and bioavailability.
Services Segment Expanding Rapidly with Growing Customisation and Scale Demand
With increasing demand for customisation and scale, the services sector is witnessing exponential growth, since academia and biotech firms are outsourcing synthesis, purification, and modification to specialised services. The spectrum of synthesis box dry capacities between 25 nmol-10,000 nmol distributed to cater for an enormous array of research and production needs. The service quality has improved with real-time quality analytics, digital ordering platforms, and a GMP-backed infrastructure for both turnaround and traceability, thereby assigning it as an income-generating segment. This shift supports smaller labs, which can now procure high-quality oligos without incurring exorbitant fixed capital investment in synthesiser infrastructure.\
Key Takeaways
- RNA Therapies Surge - RNA-based vaccines and therapeutics amplify demand for custom oligonucleotides.
- Synthesized Products Lead - Oligos remain core components in molecular biology workflows and diagnostics.
- Therapeutics Drive Growth - Increased adoption of gene-targeted therapies expands the clinical applications.
- CRISPR Fuels Research - Oligos power gene editing tools for basic and applied bioscience.
- Automation is Key - Lab automation boosts speed, precision, and reduces human error in synthesis workflows.
- AI-Driven Design - Intelligent platforms enable predictive, error-free oligo sequence optimization.
- Enzymatic Synthesis Trend - Next-gen synthesis methods support complex and long-strand DNA/RNA.
- Custom Solutions Rise - Niche applications and personalised reagents increase the need for on-demand synthesis.
- APAC Accelerates - Asia-Pacific-s biotech expansion creates a robust ecosystem for oligo manufacturing.
- Compliance Focus - Regulatory rigor around therapeutic oligos mandates GMP-certified manufacturing partners.
Regional Insights
North America: The Front Runner in Oligo Manufacturing Engineered with Advanced Infrastructure and Therapeutic Innovations
North America has the largest share in oligonucleotide synthesis, mainly due to the cutting-edge ones of biopharma infrastructures, robust funding in genomic research, and many clinical trials pertaining to oligonucleotide therapeutics. The largest chunk of the picture is taken by the U.S., with primary support from huge players such as Thermo Fisher Scientific, IDT, and Agilent Technologies. Increasing FDA approvals for antisense and RNA therapy have fuelled the local manufacturing expansion and R&D collaboration. The notable feature also came from the fact that many academic research hubs and established supply chains are backing North America's position as the worldwide leader in oligo synthesis innovation.
Europe: Strong Regulatory Framework for Green and High-Quality Oligo Synthesis
Europe is still a pace-setter for sustainable and quality-oriented oligonucleotide production; it is also the character behind the compliance with stringent EMA and REACH standards. Huge investment from Germany, the UK, and the Netherlands is being made in GMP-certified facilities and environment-friendly synthesis platforms. European companies are paving the way on circular chemistry projects - where they will concentrate on solvent recovery and production systems with less waste. The application of synthetic biology into biomanufacturing pipelines continues to energise the market momentum across the continent.
Asia-Pacific: Fastest-Growing Market Fuelled by the Expansion of Biotech and Support from the Government
Asia-Pacific is expected to grow the fastest owing to the upsurge in investment in biotechnology, genomics, and pharmaceutical production. The production and consumption centers for oligos are China and India because of government incentives for local manufacture and their progressively growing stature in global clinical trials. Such investments are also motivating countries like Japan and South Korea to come up with next-gen RNA synthesis technologies to strengthen the vaccine and therapeutic pipelines. They speak of some strategic importance to the region in the global market, with the government funding into genetic research, coupled with regional collaborations with Western biotech firms.
LAMEA: Emerging Potentials through Modernising Healthcare and the Expansion of Diagnostics
Gradually, LAMEA is making strides into the arena of oligonucleotide synthesis, guided by the expanded healthcare infrastructure and an expanding array of diagnostic capabilities in Latin America and the Middle East. Brazil and the UAE serve as major markets active in innovating molecular diagnostics as well as conducting major academic research activities. The increased emphasis in the region on self-sufficiency in biotechnology production, along with increasing investment for clinical genomics, stands to offer long-term opportunities for oligo suppliers and contract manufacturers.
Key Benefits for Stakeholders
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.
Frequently Asked Question(FAQ) :
Market growth is primarily fueled by the increasing demand for precision medicine, the rise of RNA-based therapies and vaccines, and the widespread adoption of CRISPR gene editing technologies. Additionally, the expansion of genomic research and the need for high-fidelity sequences for diagnostic applications like PCR and Next-Generation Sequencing (NGS) are significant contributors.
Leading market participants include Thermo Fisher Scientific Inc., Merck KGaA, Integrated DNA Technologies Inc. (IDT), Agilent Technologies Inc., Eurofins Genomics, LGC Biosearch Technologies, Twist Bioscience Corporation, Bio-Synthesis Inc., GenScript Biotech Corporation, and TriLink BioTechnologies.
While oligonucleotides remain the core product, the services segment is expanding rapidly. This growth is driven by academic and biotech firms outsourcing synthesis, purification, and modification to specialized providers to avoid high capital investments in synthesizer infrastructure and to leverage expert GMP-backed facilities.
Key technological innovations include enzymatic DNA synthesis, which enables longer and more accurate sequences, AI-based sequence optimization tools that reduce production failures, and the integration of microfluidic and automated high-throughput synthesis platforms to improve efficiency and yield.
North America currently holds the largest market share due to its advanced biopharmaceutical infrastructure and high R&D investment. However, the Asia-Pacific region is expected to be the fastest-growing market, driven by government incentives, expanding biotech ecosystems in China and India, and increasing regional clinical trial activities.
The market faces bottlenecks such as high production costs for therapeutic-grade oligos, stringent regulatory oversight, and the complexity of purification and validation required for GMP compliance. Additionally, a lack of global harmonization in standards for oligonucleotide therapeutics can impede cross-border collaborations.
There is a growing "Green Design" trend where manufacturers are adopting environmentally friendly synthesis reagents, solvent recycling systems, and energy-efficient purification methods. This shift is driven by both regulatory expectations and the sustainability goals of biopharma clients.
The pandemic highlighted the critical need for synthetic RNA for vaccines, emphasizing the strategic importance of scalable, automated synthesis platforms. This has led to increased investment in manufacturing resilience and the expansion of RNA-based therapeutic pipelines beyond infectious diseases into oncology and rare diseases.
Synthetic biology offers opportunities for custom-designed oligos in genome engineering, bio-circuitry, and engineered microorganisms. In the CRISPR-Cas9 field, the demand for high-fidelity guide RNA (gRNA) is central to the success of gene editing research and commercialization, creating a niche for high-purity synthesis providers.
